231 related articles for article (PubMed ID: 21799009)
1. Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction.
Gårdsvoll H; Jacobsen B; Kriegbaum MC; Behrendt N; Engelholm L; Østergaard S; Ploug M
J Biol Chem; 2011 Sep; 286(38):33544-56. PubMed ID: 21799009
[TBL] [Abstract][Full Text] [Related]
2. Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation.
Zhao B; Gandhi S; Yuan C; Luo Z; Li R; Gårdsvoll H; de Lorenzi V; Sidenius N; Huang M; Ploug M
J Mol Biol; 2015 Mar; 427(6 Pt B):1389-1403. PubMed ID: 25659907
[TBL] [Abstract][Full Text] [Related]
3. Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor.
Gårdsvoll H; Kjaergaard M; Jacobsen B; Kriegbaum MC; Huang M; Ploug M
J Biol Chem; 2011 Dec; 286(50):43515-26. PubMed ID: 22025616
[TBL] [Abstract][Full Text] [Related]
4. Sequences within domain II of the urokinase receptor critical for differential ligand recognition.
Li Y; Lawrence DA; Zhang L
J Biol Chem; 2003 Aug; 278(32):29925-32. PubMed ID: 12761227
[TBL] [Abstract][Full Text] [Related]
5. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
[TBL] [Abstract][Full Text] [Related]
6. Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM).
Xu X; Cai Y; Wei Y; Donate F; Juarez J; Parry G; Chen L; Meehan EJ; Ahn RW; Ugolkov A; Dubrovskyi O; O'Halloran TV; Huang M; Mazar AP
PLoS One; 2014; 9(1):e85349. PubMed ID: 24465541
[TBL] [Abstract][Full Text] [Related]
7. Ligand binding regions in the receptor for urokinase-type plasminogen activator.
Liang OD; Chavakis T; Kanse SM; Preissner KT
J Biol Chem; 2001 Aug; 276(31):28946-53. PubMed ID: 11501527
[TBL] [Abstract][Full Text] [Related]
8. Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor.
Nagase K; Kobayashi H; Yoshikawa E; Kurita N
J Mol Graph Model; 2009 Aug; 28(1):46-53. PubMed ID: 19403319
[TBL] [Abstract][Full Text] [Related]
9. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
[TBL] [Abstract][Full Text] [Related]
10. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.
Gårdsvoll H; Ploug M
J Biol Chem; 2007 May; 282(18):13561-72. PubMed ID: 17355965
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of the urokinase receptor in a ligand-free form.
Xu X; Gårdsvoll H; Yuan C; Lin L; Ploug M; Huang M
J Mol Biol; 2012 Mar; 416(5):629-41. PubMed ID: 22285761
[TBL] [Abstract][Full Text] [Related]
12. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase.
Chang AW; Kuo A; Barnathan ES; Okada SS
Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1855-60. PubMed ID: 9848876
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism.
Czekay RP; Loskutoff DJ
J Cell Physiol; 2009 Sep; 220(3):655-63. PubMed ID: 19472211
[TBL] [Abstract][Full Text] [Related]
14. Intermolecular contact regions in urokinase plasminogen activator receptor.
Liang OD; Bdeir K; Matz RL; Chavakis T; Preissner KT
J Biochem; 2003 Nov; 134(5):661-6. PubMed ID: 14688231
[TBL] [Abstract][Full Text] [Related]
15. Discovery of new small molecules targeting the vitronectin-binding site of the urokinase receptor that block cancer cell invasion.
Rea VE; Lavecchia A; Di Giovanni C; Rossi FW; Gorrasi A; Pesapane A; de Paulis A; Ragno P; Montuori N
Mol Cancer Ther; 2013 Aug; 12(8):1402-16. PubMed ID: 23699658
[TBL] [Abstract][Full Text] [Related]
16. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.
Chavakis T; Kanse SM; Yutzy B; Lijnen HR; Preissner KT
Blood; 1998 Apr; 91(7):2305-12. PubMed ID: 9516128
[TBL] [Abstract][Full Text] [Related]
17. A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor.
Hillig T; Engelholm LH; Ingvarsen S; Madsen DH; Gårdsvoll H; Larsen JK; Ploug M; Danø K; Kjøller L; Behrendt N
J Biol Chem; 2008 May; 283(22):15217-23. PubMed ID: 18362146
[TBL] [Abstract][Full Text] [Related]
18. Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization.
Sidenius N; Andolfo A; Fesce R; Blasi F
J Biol Chem; 2002 Aug; 277(31):27982-90. PubMed ID: 12034711
[TBL] [Abstract][Full Text] [Related]
19. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
Salasznyk RM; Zappala M; Zheng M; Yu L; Wilkins-Port C; McKeown-Longo PJ
Matrix Biol; 2007 Jun; 26(5):359-70. PubMed ID: 17344041
[TBL] [Abstract][Full Text] [Related]
20. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration.
Yebra M; Parry GC; Strömblad S; Mackman N; Rosenberg S; Mueller BM; Cheresh DA
J Biol Chem; 1996 Nov; 271(46):29393-9. PubMed ID: 8910604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]